The Utility Of Minimal Residual Disease (MRD) Assessment At First Relapse: Results From The BSBMT/Ukmf Myeloma X (Intensive) Trial

被引：1
|
作者：
Ashcroft, John
de Tute, Ruth M.
Cairns, David A.
Fletcher, Marie
Owen, Roger G.
Rawstron, Andy
O'Connor, Sheila J. M.
Williams, Cathy D.
Snowden, John A.
Cavenagh, J. D.
Parrish, Christopher
Morris, Treen
Brown, Julia M. B.
Cook, Gordon
机构：
来源：
BLOOD | 2013年 / 122卷 / 21期
关键词：
D O I：
10.1182/blood.V122.21.3378.3378
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3378
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Relapse in Teenage and Young Adult (TYA) Patients Treated on a Pediatric Minimal Residual Disease (MRD) Stratified Protocol Is Associated with a Poor Outcome: Results from UKALL2003
    Sellar, Rob S.
    Rowntree, Clare
    Vora, Ajay J.
    Furness, Caroline L.
    Goulden, Nicholas
    Mitchell, Chris
    Moorman, Anthony V.
    Hough, Rachael
    BLOOD, 2015, 126 (23)
  • [42] A Comprehensive and Systematic Analysis of Minimal Residual Disease (MRD) Monitoring in Follicular Lymphoma: Results from the Fondazione Italiana Linfomi (FIL) FOLL12 Trial
    Ladetto, Marco
    Ferrero, Simone
    Del Giudice, Ilaria
    Galimberti, Sara
    Gattei, Valter
    Marcheselli, Luigi
    Mantoan, Barbara
    Genuardi, Elisa
    Alessandria, Beatrice
    Ferrante, Martina
    Dogliotti, Irene
    Della Starza, Irene
    De Novi, Lucia Anna
    Cavalli, Marzia
    Grassi, Susanna
    Ciabatti, Elena
    Guerrini, Francesca
    Bomben, Riccardo
    Degan, Massimo
    Zaina, Eva
    Perrone, Tommasina
    Petrini, Mario
    Re, Francesca
    Olivieri, Attilio
    Usai, Sara Veronica
    Mannina, Donato
    Falini, Brunangelo
    Scalabrini, Delia Rota
    Stefani, Pietro Maria
    Ballerini, Filippo
    Federico, Massimo
    Luminari, Stefano
    BLOOD, 2021, 138
  • [43] Induction Quadruplet Therapy and Minimal/Measurable Residual Disease (MRD)-Informed Treatment Adaptation in Newly Diagnosed Multiple Myeloma (NDMM): Results from an Academic-Community Pathway
    Ravi, Gayathri
    Giri, Smith
    Bal, Susan
    Godby, Kelly N.
    Reddy, Vishnu V. B.
    Salzman, Donna
    Alkharabsheh, Omar
    McDaniel, Scott A.
    Sentell, Melissa
    Costa, Luciano J.
    BLOOD, 2022, 140 : 8048 - 8049
  • [44] Frequent detection of minimal residual disease (MRD) in autografts from patients with multiple myeloma during remission using a new culture method.
    Cohen, Y
    Hardan, Y
    Nagler, A
    Zipori, D
    BLOOD, 2004, 104 (11) : 302B - 302B
  • [45] Predictors of unsustained negativity in minimal residual disease (MRD)-negative transplant-eligible newly diagnosed multiple myeloma (MM) patients enrolled in the FORTE trial
    D'Agostino, Mattia
    Oliva, Stefania
    Rota-Scalabrini, Delia
    Petrucci, Maria Teresa
    Zambello, Renato
    De Sabbata, Giovanni
    Liberati, Anna Marina
    Pietrantuono, Giuseppe
    Tosi, Patrizia
    Pisani, Francesco
    Capra, Andrea
    Velluti, Cristina
    Galieni, Piero
    Annibali, Ombretta
    Monaco, Federico
    Pascarella, Anna
    Palmieri, Salvatore
    Luppi, Mario
    Cavo, Michele
    Paris, Laura
    Bruno, Benedetto
    Musto, Pellegrino
    Boccadoro, Mario
    Gay, Francesca
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S6 - S7
  • [46] The relevance of minimal residual disease after autologous stem cell transplantation in patients with multiple myeloma (first results of a prospective study)
    Solovev, M.
    Mendeleeva, L.
    Galtseva, I.
    Pokrovskaya, O.
    Firsova, M.
    Nareyko, M.
    Kuzmina, L.
    Gemdzhian, E.
    Savchenko, V.
    BONE MARROW TRANSPLANTATION, 2016, 51 : S506 - S507
  • [47] Prospective trial of minimal residual disease assessment by multiparametric flow cytometry for multiple myeloma in the era of bortezomib-based chemotherapy
    Clark, C. Amos
    Mosse, Claudio A.
    Chen, Heidi
    Byrne, Michael
    Chinratanalab, Wichai
    Engelhardt, Brian G.
    Goodman, Stacey A.
    Harrell, Shelton L.
    Kassim, Adetola A.
    Savani, Bipin N.
    Sengsayadeth, Salyka
    Jagasia, Madan
    Cornell, R. Frank
    BONE MARROW TRANSPLANTATION, 2018, 53 (12) : 1589 - 1592
  • [48] Prospective trial of minimal residual disease assessment by multiparametric flow cytometry for multiple myeloma in the era of bortezomib-based chemotherapy
    C. Amos Clark
    Claudio A. Mosse
    Heidi Chen
    Michael Byrne
    Wichai Chinratanalab
    Brian G. Engelhardt
    Stacey A. Goodman
    Shelton L. Harrell
    Adetola A. Kassim
    Bipin N. Savani
    Salyka Sengsayadeth
    Madan Jagasia
    R. Frank Cornell
    Bone Marrow Transplantation, 2018, 53 : 1589 - 1592
  • [49] Prospective Trial of Minimal Residual Disease Assessment by Multiparametric Flow Cytometry for Multiple Myeloma in the Era of Bortezomib-Based Chemotherapy
    Cornell, Robert F.
    Mosse, Claudio A.
    Chen, Heidi
    Byrne, Michael T.
    Chinratanalab, Wichai
    Engelhardt, Brian G.
    Goodman, Stacey
    Kassim, Adetola A.
    Savani, Bipin N.
    Sengsayadeth, Salyka
    Jagasia, Madan
    Clark, Charles Amos
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2018, 24 (03) : S137 - S138
  • [50] Early Assessment of Minimal Residual Disease (MRD) by Qualitative PCR for NPM-ALK Identifies Patients At Very High Risk of Relapse in Anaplastic Large Cell Lymphoma
    Damm-Welk, Christine
    Mussolin, Lara
    Pillon, Marta
    Zimmermann, Martin
    Reiter, Alfred
    Woessmann, Wilhelm
    Rosolen, Angelo
    BLOOD, 2011, 118 (21) : 680 - 680
12345